CD40 and cancer: Yet, agonistic anti-CD40 (αCD40) monoclonal antibodies mimic CD40L in vivo and have been shown to enhance the immunogenicity of cancer vaccines and trigger cancer regressions [122,123,124], including in pancreatic cancer [125].